People with anorexia nervosa and with body dysmorphic disorder have similar abnormalities in their brains that affect their ability to process visual information, according to a new study.

People with anorexia have an intense fear of gaining weight and can starve themselves even when they are dangerously thin. Body dysmorphic disorder is a psychiatric condition characterized by an obsessive preoccupation with a perceived flaw in physical appearance.

The St. Jude Children's Research Hospital--Washington University Pediatric Cancer Genome Project reports that a highly aggressive form of leukemia in infants has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene. The findings suggest that targeting the alteration is likely the key to improved survival. The research appeared online ahead of print this week in the scientific journal Nature Genetics.

In the absence of food, neurons that normally control appetite initiate complex, repetitive behaviors seen in obsessive-compulsive disorder (OCD), and anorexia nervosa, according to a new study by Yale School of Medicine researchers.

The findings are published in the March 5 online issue of the journal Cell.

Neural circuits are responsible for flexible goal-oriented behaviors. The Yale team investigated how a population of neurons in the hypothalamus that control food intake are also involved in other behaviors. Known as Agrp neurons, these cells also control repetitive, stereotypic behaviors in mice when food is not available, the researchers discovered.

A new testosterone nasal gel raises men's low testosterone levels to normal, with few side effects, according to the results of a phase 3 clinical trial to be presented Saturday at the Endocrine Society's 97th annual meeting in San Diego.

Last May, the U.S. Food and Drug Administration approved the medication, now called Natesto, making it the only FDA-approved nasal testosterone replacement therapy, according to the manufacturer, Trimel Pharmaceuticals.

Using a mouse model of rheumatoid arthritis, scientists have discovered that a form of cellular immunotherapy by intravenous administration of monocytic myeloid-derived suppressor cells, or M-MDSCs, might be an effective treatment for the disease in humans. In a report published in the March 2015 issue of the Journal of Leukocyte Biology, researchers show that M-MDSCs are capable of inhibiting T cell proliferation, as well as B cell proliferation and antibody production. As a result, the arthritic mice experienced improvements in their symptoms.

The molecular complex that guides an important class of proteins to correct locations in cell membranes does so by forming a dimeric structure with a protective pocket, according to a new report. This structure shields tail-anchored membrane proteins - which have roles in a wide variety of cellular functions from neurotransmitter release to insulin production - from harmful aggregation or misfolding as they move through the inner environment of a cell. The findings clarify the mechanism behind a fundamental biological process.